SGLT-2 Therapy Center

Diabetes is the leading cause of chronic kidney disease due to microvascular damage to the renal blood vessels.

Researchers investigate the changes in ambulatory blood pressure using the antidiabetic drug in patients with type 2 diabetes and hypertension.

Contrary to previous studies, new research finds SGLT-2i more effective for weight loss than GLP-1 RAs as add-on therapy to Metformin. 

Male, 72 years of age, type 2, insulin-requiring diabetes, also taking SGLT-2. Annual physical. No urinary complaints during the visit. Received annual lab work end of the workday, glucose elevated much higher than the reports. WBC elevated, 1200, no urine culture, but U/A did show cloudy....

Dapagliflozin has shown clinical effectiveness in some of the same metabolic processes that are affected by COVID-19, but can it help treat patients who have contracted the virus?

American Diabetes Association mini-symposium presented by Biykem Bozkurt, MD, Ph.D., FHFSA, FACC, FAHA, FESC. 

The study evaluates the healthcare cost associated with two principal therapies for patients with type 2 diabetes.  

After starting SGLT-2i, is the discontinuation of therapy necessary if there is an immediate decline in estimated Glomerular Filtration Rate (eGFR) in patients?

Study finds incidence of type 2 diabetes reduced by 32% in participants taking dapagliflozin vs. placebo. 

Type 1 diabetes mellitus patients with high BMI and hypoglycemia may improve quality of life through dapagliflozin treatment.